Patents Assigned to Sloan Kettering Institute
-
Patent number: 9592238Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.Type: GrantFiled: August 23, 2013Date of Patent: March 14, 2017Assignees: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
-
Publication number: 20170066712Abstract: This invention provides a compound having the structure: wherein R1 is H, halogen, —NR5R6, —NR5—C(?0)-R6, —NH—C(?O)—OR7, —OR7, —NO2, —CN, —SR7, —SO2R7, —CO2R7, CF3, —SOR7, —POR7, —C(?S)R7, —C(?O)—NR5R6, —CH2—C(?O)—NR5R6, —C(?NR5)R6, —P(?O)(OR5)(OR6), —P(OR5)(OR6), —C(?S)R7, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, or heterocyclyl, wherein R5, R6, and R7 and are each, independently, H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; m is an integer from 0 to 2; R2 and R3 are each, independently, H, halogen, —NH2, —CX3, —C(?O)OR8, C(?O)R8, —C(?O)NR9R10, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, heteroalkyl, aryl, heteroaryl, or heterocyclyl; wherein X is Cl, Br, or F; R8, R9 and R10 are each, independently, H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Q is —Ar1—Z— or —Z—Ar1—Z—, wherein Ar1 is aryl or heteroaryl; and each occurrence of Z is independently present orType: ApplicationFiled: November 18, 2016Publication date: March 9, 2017Applicants: The Trustees of Columbia University in the City of New York, Sloan-Kettering Institute for Cancer ResearchInventors: Ronald Breslow, Paul A. Marks
-
Patent number: 9572875Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.Type: GrantFiled: October 1, 2015Date of Patent: February 21, 2017Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Philip O. Livingston, Govindaswami Ragupathi, Samuel J. Danishefsky
-
Patent number: 9562019Abstract: The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries.Type: GrantFiled: December 21, 2007Date of Patent: February 7, 2017Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Hakim Djaballah, Harold E. Varmus, David Shum, Romel Somwar, Alexander Chucholowski, Mohan Santhanam Thiruvazhi
-
Publication number: 20170029525Abstract: Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis.Type: ApplicationFiled: August 31, 2016Publication date: February 2, 2017Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Xingxing Zang, James P. Allison
-
Patent number: 9555137Abstract: The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6).Type: GrantFiled: July 6, 2012Date of Patent: January 31, 2017Assignees: Sloan-Kettering Institute for Cancer Research, Cornell UniversityInventors: Gabriela Chiosis, Tony Taldone, Mary L. Alpaugh, Erica M. Gomes-Dagama, Monica L. Guzman, Hongliang Zong
-
Patent number: 9546146Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: GrantFiled: March 9, 2016Date of Patent: January 17, 2017Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Samuel J. Danishefsky, Joan Massague, Manuel Valiente Cortes, Thordur Oskarsson, Malcolm Moore, Nicolas Lecomte, Ouathek Ouerfelli, Guangli Yang
-
Patent number: 9546170Abstract: The disclosure relates to Compounds of Formula (1) : and pharmaceutically acceptable salts thereof wherein Z1, Z2, Z3, Xa, Xb, Xc, Y, X2, and X4 are as defined herein, compositions comprising an effective amount of a Compound of Formula (1) or a pharmaceutically acceptable salt thereof, and methods to treat or prevent a condition, such as cancer which overexpresses Her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a Compound of Formula (1) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 5, 2012Date of Patent: January 17, 2017Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Tony Taldone, Gabriela Chiosis
-
Patent number: 9539272Abstract: This invention provides methods for treating a subject afflicted with cancer, comprising concurrently administering (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide. This invention also provides methods for inducing the death of a transformed cell such as a cancer cell, comprising concurrently contacting the cell with (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide.Type: GrantFiled: July 2, 2010Date of Patent: January 10, 2017Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Paul A. Marks, Weisheng Xu, Mandana Namdar
-
Publication number: 20160368948Abstract: This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.Type: ApplicationFiled: January 14, 2016Publication date: December 22, 2016Applicant: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: David A. Scheinberg, Rena May
-
Patent number: 9512103Abstract: A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.Type: GrantFiled: March 24, 2015Date of Patent: December 6, 2016Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ouathek Ouerfelli, Anna Dilhas, Guangbin Yang, Hong Zhao
-
Patent number: 9499479Abstract: This invention provides a compound having the structure: wherein R1 is H, halogen, —NR5R6, —NR5—C(?O)—R6, —NH—C(?O)—OR7, —OR7, —NO2, —CN, —SR7, —SO2R7, —CO2R7, CF3, —SOR7, —POR7, —C(?S)R7, —C(?O)—NR5R6, —CH2—C(?O)—NR5R6, —C(?NR5)R6, —P(?O)(OR5)(OR6), —P(OR5)(OR6), —C(?S)R7, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteroaryl, or heterocyclyl, wherein R5, R6, and R7 and are each, independently, H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; m is an integer from 0 to 2; R2 and R3 are each, independently, H, halogen, —NH2, —CX3, —C(?O)OR8, C(?O)R8, —C(?O)NR9R10, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, heteroalkyl, aryl, heteroaryl, or heterocyclyl; wherein X is Cl, Br, or F; R8, R9 and R10 are each, independently, H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Q is —Ar1—Z— or —Z—Ar1—Z—, wherein Ar1 is aryl or heteroaryl; and each occurrence of Z is independently present orType: GrantFiled: October 3, 2012Date of Patent: November 22, 2016Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Ronald Breslow, Paul A. Marks
-
Patent number: 9493580Abstract: Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.Type: GrantFiled: June 10, 2011Date of Patent: November 15, 2016Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Govind Ragupathi, Philip O. Livingston, Jianglong Zhu, David R. Spriggs
-
Patent number: 9492427Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.Type: GrantFiled: November 9, 2015Date of Patent: November 15, 2016Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
-
Patent number: 9487751Abstract: The present invention relates to methods of isolating a purified or enriched population of cortical or striatal immature interneuron progenitor cells and the isolated purified or enriched population of immature interneuron progenitor cells. Methods of treating a condition mediated by a loss or deficiency of interneuron function using the purified or enriched population of immature interneuron progenitor cells are also disclosed.Type: GrantFiled: June 2, 2010Date of Patent: November 8, 2016Assignees: CORNELL UNIVERSITY, SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Stewart A. Anderson, Asif Maroof, Lorenz Studer
-
Patent number: 9481724Abstract: Polypeptides that bind to DC-SIGN and/or its homologues and methods for using such peptides for the treatment of various disorders are described. DC-SIGN and its homologues are receptors that bind IgG antibodies or Fc fragments and mediate intravenous immunoglobulin (IVIG)-related reversal of inflammation associated with various immune disorders.Type: GrantFiled: December 10, 2012Date of Patent: November 1, 2016Assignees: The Rockefeller University, Sloan-Kettering Institute for Cancer ResearchInventors: Jeffrey Ravetch, Andrew Pincetic, Ping Wang, Sam Danishefsky
-
Patent number: 9481663Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.Type: GrantFiled: June 4, 2013Date of Patent: November 1, 2016Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer ResearchInventors: Anna Dilhas, Mark R Herbert, Ouathek Ouerfelli, Nicholas D Smith
-
Patent number: 9480700Abstract: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.Type: GrantFiled: July 21, 2014Date of Patent: November 1, 2016Assignee: Sloan-Kettering Institute for Cancer ResearchInventor: Nai-Kong V. Cheung
-
Patent number: 9464116Abstract: The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein.Type: GrantFiled: January 6, 2014Date of Patent: October 11, 2016Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Jennifer R. Allen, Govindaswami Ragupathi, Philip O. Livingston, Lawrence Williams
-
Patent number: 9447186Abstract: Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis.Type: GrantFiled: October 10, 2013Date of Patent: September 20, 2016Assignees: Albert Einstein College of Medicine, Inc., Sloan-Kettering Institute for Cancer ResearchInventors: Xingxing Zang, James P. Allison